Handbook of Clinical medicine

seeing the ghostly image she cried ‘I have seen my death!’ Could this exclamation have prophesized the ra- diation-induced malignancies that have plagued the recipients (and administrators) of X-rays since their conception (see BOX)? Despite the obvious commercial potential, Röntgen declined to take out any patents on his new technology, preferring to see it developed for the benefi t of humanity. Fate did not repay this generosity: his personal wealth depreciated away in the German hyperinfl ation of the 1920s, and he spent his later years in bankruptcy. Reproduced under Creative Commons Attribution only licence CC BY 4.0 from Wellcome Library, London, image-of-the-month-the-left-hand-of-anna-roentgen We thank Professor Peter Scally, Dr Dean McCoombe, and Dr Paul Thomas, our Specialist Readers for this chapter. __OOHHCCMM__1100ee..iinnddbb 771188 0022//0055//22001177 1199::0088 Typical eff ective doses 719 The eff ective dose of an examination is calculated as the weighted sum of the doses to diff erent body tissues. The weighting factor for each tissue depends on its sensitivity. The eff ective dose thus provides a single dose estimate related to the total radiation risk, no matter how the radiation dose is distributed around the body. This table is certainly not to be learnt; rather it serves as
